LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems announces the installation of the first MEVION S250i with HYPERSCAN, Mevion’s advanced proton therapy pencil beam scanning system, at MedStar Georgetown University Hospital. This breakthrough technology will allow MedStar Georgetown to deliver a new standard of Intensity Modulated Proton Therapy (IMPT) combining the fastest energy modulation with the sharpest lateral penumbra improving the treatment options available to cancer patients. This is the first installation of HYPERSCAN with Adaptive Aperture, Mevion’s novel proton multi-leaf collimator. The installation at MedStar Georgetown will be followed by a MEVION S250i installation at Zuidoost Nederland Protonen Therapie Centrum, co-located at the Maastricht Clinic, in the Netherlands and at the Ackerman Cancer Center in Jacksonville, Florida, which will be the second unit installed at the private, physician-run center.
“Mevion is proud to be working with MedStar Georgetown to achieve this milestone, and to be making proton therapy accessible to the Washington D.C. area. HYPERSCAN with Adaptive Aperture represents a real paradigm shift for the entire industry. This is the only proton system able to precisely shape each energy layer and deliver those layers at speeds up to 50 times faster than other systems. The results are highly conformal proton dose distributions that can be automatically adapted as treatment progresses,” said Joseph K. Jachinowski, president and CEO of Mevion Medical Systems.
The Adaptive Aperture is a proprietary low-profile micro-multi-leaf collimator system designed specifically for HYPERSCAN pencil beam scanning. It eliminates the need for manual apertures and adjustments because its unique layer-by-layer beam collimation achieves unprecedented one to three millimeter collimated effective spot sizes for all energies. HYPERSCAN with Adaptive Aperture is capable of scanning a typical lung tumor in less than two seconds – eliminating many of the challenges caused by patient motion that other pencil beam scanning systems encounter.
Proton therapy provides targeted radiation treatment for many types of cancer, significantly reducing the dose of radiation to healthy tissue by as much as a factor of three, while still maintaining high conformance to the treatment target. Mevion developed the world’s first compact proton therapy system to help increase access to this valuable therapy and currently has more compact systems under contract, installed and treating patients than any other proton therapy manufacturer.
About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with offices in the Netherlands, Japan and China. For more information, please visit www.mevion.com.
About the MEVION S250 Series™
The MEVION S250 Series is elegantly designed to deliver high-powered, efficient proton therapy treatments. Built upon the world’s only gantry-mounted proton accelerator and benefitting from Mevion’s patented direct beam technology, the MEVION S250 Series delivers on the therapeutic promise of proton therapy while enhancing beam quality, stability and uptime. The result is a high-quality treatment with reduced system complexity, higher reliability and throughput, and lower capital and operating costs—making the MEVION S250 Series a compelling, financially viable solution for all cancer centers. The MEVION S250 Series includes:
- MEVION S250 Proton Therapy System®, offering highly stable, next-generation volumetric delivery capabilities
- MEVION S250i Proton Therapy System™ with HYPERSCAN™ and Adaptive Aperture™, overcoming pencil beam scanning uncertainties by delivering robust IMPT treatment at hyper-speed
- MEVION S250mx™, making proton therapy fully scalable, with two, three and four room designs that are inherently redundant and support 100% facility uptime
The MEVION S250i Proton Therapy System with HYPERSCAN and Adaptive Aperture has not been cleared by the USFDA for clinical use.